Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

A mum’s “back pain” while bowling with her family at Center Parcs turned out to be a sinister symptom of advanced breast ...

An expert discusses how treatment decisions in metastatic castration-resistant prostate cancer (mCRPC) increasingly depend on prior androgen receptor pathway inhibitor (ARPI) exposure, highlighting ...

Stephanie Walker was diagnosed with metastatic breast cancer (MBC) nearly a decade ago — an experience she says transformed ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

A team of researchers at the University of Minnesota recently completed a human trial for a novel gene-editing treatment, ...

The FDA has approved Nubeqa (darolutamide), an androgen receptor inhibitor, for the treatment of mCSPC in adults.

New research in the June 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that older people ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.